Anlon Healthcare Limited — Q4 FY26 earnings call

Call held 3 Jun 2026

Management summary

AHCL reported strong financial growth for FY26, with significant increases in total income, EBITDA, and PAT, driven by strategic acquisitions and capacity expansion. However, Q4 FY26 PAT was lower due to increased operating costs and raw material price volatility. The company provided optimistic guidance for FY27 and FY28 revenue, while addressing concerns regarding working capital management and aiming for positive cash flow by FY27 end.

Highlights

  • Strong financial growth in FY26 with Total Income up 42.98% YoY to INR 172.22 crore.

  • EBITDA increased 47.55% to INR 47.77 crore and PAT grew 41.77% to INR 29.09 crore for FY26.

  • Completed acquisitions of Apiqo Organics and Bizotic Life Science, strengthening backward integration and capacity.

  • Expanded installed capacity to 1400-1600 metric tons per annum, positioning for future growth.

  • Guidance for 30% revenue CAGR over the next three years and FY27 revenue target of INR 380-400 crore.

Concerns

  • Q4 FY26 PAT was lower at INR 11.07 crore compared to INR 16.65 crore in Q4 FY25, primarily due to higher operating and development expenses.

  • EBITDA margin impacted by raw material price volatility and global supply chain disturbances.

  • High receivable days, currently at 200+ days, with a target to reduce to 180 days by FY27 end.

  • Steep jump in inventories and other financial assets due to acquisitions and raw material price increases.

Key financials

3 periods

Headline

  • Consolidated EBITDA Margin
    24%

Q4 FY26

  • Total Income
    ₹50.9 Cr
    YoY +3.9%
  • PAT
    ₹11.07 Cr
    YoY -33.5%

FY26

  • Total Income
    ₹172.22 Cr
    YoY +43%
  • EBITDA
    ₹47.77 Cr
    YoY +47.5%
  • PAT
    ₹29.09 Cr
    YoY +41.8%

What they filed

Q1 FY27: revenue up 162.9%, net profit up 133.2% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue24 9 49 33 52 +116%36 +280%51 +4%88 +163%
EBITDA8 1 17 6 14 +83%12 +2017%15 −11%16 +150%
Net profit3 -2 17 4 9 +260%5 +307%11 −34%8 +133%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Order book

high confidence

Total value

₹280 Cr

as of 2026-03-31 range

Execution

for the whole year

The company has clear visibility for INR 280-300 crore in orders for the full year on a consolidated basis, with potential for an additional INR 80-90 crore.

Source: Q&A

Capital allocation

high confidence
  • Capex ₹130 Cr INR 65-70 crore from bank term loan, remaining from internal funds
    • New facility expansion in existing Anlon Healthcare premises ₹130 Cr
    The basic plant layout is almost under the approval and we are expecting by mid of this month, so we are planning to start the construction activity by end of this month or maybe early next month, and the Capex is expected somewhere around INR130 CR. ... for the expansion of the facility, we are planning to get some in terms of term loan from the bank for the at least INR 65 to 70 CR of the term loan and remaining from internal funds.
  • Debt Debt disclosed
    • New borrowing Planning to get INR 65-70 crore term loan from bank for Capex funding. ₹65 Cr
    for the expansion of the facility, we are planning to get some in terms of term loan from the bank for the at least INR 65 to 70 CR of the term loan and remaining from internal funds.
  • M&A Apiqo Organics Private Limited Acquisition · Closed

    Strengthened backward integration and added substantial capacity.

    We completed the acquisition of Apiqo Organics Private Limited, which strengthened backward integration and added substantial capacity
  • M&A Bizotic Life Science Acquisition · Closed

    Accelerated capacity expansion and regulatory readiness.

    we completed the acquisition of Bizotic Life Science, now a subsidiary of Anlon Healthcare, further accelerating capacity expansion and regulatory readiness.
  • M&A Remember Pharma Acquisition · Closed
    See, because it was acquired in this FY27, that's why it was not mentioned in this presentation, I think.
  • Liquidity Liquidity disclosed Company expects to be cash flow positive by the end of FY27, with funding for Capex from internal accruals and debt, without equity dilution.
    I think as I have mentioned that by end of FY27, cash flow I'm very much sure that it will be positive. ... See, right now we are not having any plan for the dilution of any equity. But yes, for the expansion of the facility, we are planning to get some in terms of term loan from the bank for the at least INR 65 to 70 CR of the term loan and remaining from internal funds.

Guidance & targets

Revenue

  • FY27 Revenue Revenue · FY27 · High confidence INR 380-400 CR
    That should be right now the whatever the visibility we are having, it is between INR 380 to 400 CR for FY27.

    — Punit Rasadia

  • FY28 Revenue Revenue · FY28 · High confidence INR 700-800 CR
    Yeah, FY28 we are expecting between 700 to 800 CR.

    — Punit Rasadia

  • Revenue CAGR Revenue · next three years · High confidence 30%
    we remain confident of delivering approximately 30% of revenue CAGR over the next three years while working towards maintaining EBITDA margin in the range of 25 to 30%.

    — Punit Rasadia

Profitability

  • Consolidated EBITDA Margin Profitability · FY27 & FY28 · High confidence 24-25%
    so overall our EBITDA margin what we are expecting that would be between 24-25%.

    — Punit Rasadia

  • FY27 PAT Profitability · FY27 · Medium confidence INR 45-55 CR
    Yeah, we are right now actually on the conservative side, we are expecting the INR 45 CR of the PAT. ... Yeah, yeah, it should be. (in response to 50-55 CR)

    — Punit Rasadia

Product Pipeline

  • New API Launches Product Pipeline · FY27 · High confidence 7 new APIs
    our priorities remain focused on launching of seven new APIs in FY27 across additional therapeutic categories

    — Punit Rasadia

  • Additional DMF Filings Product Pipeline · FY27 · High confidence 3-5 DMFs
    filing three to five additional DMF in FY27 to deepen regulated market penetration and long-term revenue visibility

    — Punit Rasadia

Sales Mix

  • Export Contribution Sales Mix · FY27 · High confidence 60%
    as earlier we have also mentioned that we are trying to do the at least somewhere around 60% of the export contribution in this FY27.

    — Punit Rasadia

Receivables

  • Receivable Days Receivables · FY27 end · Medium confidence 180 days
    And by end of this FY27 with the positive cash flow and receivable days will remain at least 180 days, which is I think mostly API manufacturer is having.

    — Punit Rasadia

Inventory

  • Inventory Reduction Inventory · FY27 end · Medium confidence 20-25%
    But I think we'll reduce our inventory whatever right now here in Q2 somewhere around 20 to 25% will be liquidated without any doubt. ... so this reduction 20 to 25%, this is expected at the end of next year.

    — Punit Rasadia

Market context

  • Cash Flow Cash Flow · FY27 end · High confidence Positive
    I think as I have mentioned that by end of FY27, cash flow I'm very much sure that it will be positive.

    — Punit Rasadia

What to watch in Q1 FY27

Cash Flow Positivity

FY27 end
Current Negative in Q4 FY26 (-47 crores)
Target Positive cash flow

Why it matters

Achieving positive cash flow is crucial for financial stability and funding future growth without external equity.

I think as I have mentioned that by end of FY27, cash flow I'm very much sure that it will be positive.

Risks & concerns

  • Raw material price volatility and global supply chain disturbance

    medium

    Prices of raw material and global supply chain are disturbed, impacting EBITDA margins, though company is trying to pass on costs.

    Management acknowledged

  • High receivable days impacting cash flow

    medium

    Receivable days are currently over 200 days, impacting cash flow, with a target to reduce to 180 days by FY27 end through stricter payment terms.

    Analyst acknowledged

  • Higher operating and development expenses

    low

    Contributed to lower Q4 FY26 PAT as the company scales its platform and becomes more professional.

    Management acknowledged

  • Credit rating 'issuer not cooperating' remark

    low

    A historical issue with CARE Ratings, which the company is resolving by applying for a fresh rating with Brickwork, expecting BBB- minimum.

    Analyst acknowledged

Q&A highlights

8 direct
FY27 and FY28 Revenue Guidance & Peak Capacity Direct
That should be right now the whatever the visibility we are having, it is between INR 380 to 400 CR for FY27. ... I think we may go up to the INR 450 to INR 500 CR in the peak capacity of the consolidation. ... Yeah, FY28 we are expecting between 700 to 800 CR.

Clarifies the company's revenue targets for the next two fiscal years and the maximum revenue potential from current capacity.

Asked by Disha

EBITDA Margins Post-Acquisition Direct
See, in Apiqo, I think the EBITDA margin was little bit lower being a chemical or intermediate manufacturing or products of that category. It will not be the same as the Pharma. Uh, but in Bizotic we'll try to keep the almost similar margin as Anlon, so overall our EBITDA margin what we are expecting that would be between 24-25%.

Provides clarity on the expected consolidated EBITDA margins, factoring in the acquired entities with different margin profiles.

Asked by Disha

Inventory Jump and Other Financial Assets Direct
So in part of the Anlon, now we are, we have just acquired the Apiqo in the I guess first week of the January, so that set of inventory whatever will be there and in terms of the Bizotic, so that impacted on our balance sheet, but that will be already sold in the first quarter of this FY27... Yeah, that advance payment we have already made against the Capex what we are trying to do in the Anlon...

Explains the reasons behind the increase in inventories (acquisitions, raw material prices) and other financial assets (Capex advances), addressing investor concerns about balance sheet items.

Asked by Paras Chheda

Current Order Book for FY27 Direct
See, right now we have the clear visibility in terms of the order book is somewhere around INR 280 to 300 CR for the whole year in consolidation basis. But we are sure that within the year, additional INR 80 to 90 CR business on the basis of the product that we can clear it. So we are expecting on basis of that 380 to 400 CR, but clear order book right now we are having between 280 to 300 CR.

Quantifies the current order book visibility for the upcoming fiscal year, providing a basis for revenue projections.

Asked by Paras Chheda

CDMO Commercialization Timeline Direct
See, one product out of three, that is already supplied for the in the validation stage... commercial supply should be expected by third quarter of FY27 and other two molecules' validation is expected by the second quarter of FY27. So I think that commercialization we can expect by last quarter of FY27 or from the first quarter of FY28.

Outlines the expected timelines for commercializing products under CDMO opportunities, indicating future revenue streams.

Asked by Paras Chheda

Cash Flow Positive Timeline Direct
Mostly FY end of FY27, it will be positive. ... On annual basis FY27 will have the positive cash flow.

Provides a clear timeline for when the company expects to achieve positive cash flow from operations, a key financial health indicator.

Asked by Paras Chheda

High Receivable Days Direct
On receivable side, you said the market norm is around 120 to 150 days. We are still at 200 plus days on receivable side. So any thoughts on that? ... And by end of this FY27 with the positive cash flow and receivable days will remain at least 180 days...

Highlights the ongoing challenge with high receivable days and management's plan to reduce them, which is crucial for working capital efficiency.

Asked by Rudraksh Raheja

Funding Mix for New Capex Direct
See, we don't want to go for any equity dilution. Right now we'll go with the bank loan, term loan for the around INR 65 to 70 CR... and whatever the remaining funds required for the Capex, that we believe that from the profit and the other that working capital whatever is the fund that we are expecting within this next four to six month, out of that we'll complete the new facility.

Clarifies the company's capital allocation strategy for the new Capex, emphasizing debt and internal accruals over equity dilution.

Asked by Purva Shah

3 min read 7 chapters

Detailed narrative

FY26 Financial Performance and Q4 Overview

Anlon Healthcare Limited delivered strong financial growth in FY26, with total income increasing by 42.98% year-on-year to INR 172.22 crore. EBITDA saw a 47.55% rise to INR 47.77 crore, and profit after tax grew by 41.77% to INR 29.09 crore. This performance was attributed to expanding demand, improved operational efficiencies, and disciplined execution. For Q4 FY26, total income stood at INR 50.90 crore, a modest increase from INR 48.97 crore in Q4 FY25, but reported PAT was lower at INR 11.07 crore compared to INR 16.65 crore in the corresponding quarter, mainly due to higher operating and development expenses.

Strategic Acquisitions and Capacity Expansion

FY26 marked a significant phase in Anlon's growth journey with the completion of two key acquisitions. The company acquired Apiqo Organics Private Limited, which strengthened backward integration and added substantial capacity. Additionally, the acquisition of Bizotic Life Science, now a subsidiary, further accelerated capacity expansion and regulatory readiness. These acquisitions have expanded the combined installed capacity to approximately 1400 to 1600 metric tons per annum, positioning the company for its next phase of scale growth. The company also acquired Remember Pharma in FY27.

FY27 and FY28 Revenue Outlook

Management provided optimistic revenue guidance, targeting INR 380-400 crore for FY27. With the current consolidated capacity, the peak revenue potential is estimated to be INR 450-500 crore. Looking further ahead, the company expects to achieve INR 700-800 crore in revenue for FY28. This growth is anticipated to be driven by new API launches, additional DMF filings, and expanding CDMO engagement, with a projected revenue CAGR of 30% over the next three years.

EBITDA Margin and Operational Challenges

The consolidated EBITDA margin is expected to be maintained in the range of 24-25% for FY27 and FY28. While Apiqo's EBITDA margin is slightly lower (22-23%) due to its chemical/intermediate nature, Bizotic is expected to maintain margins similar to Anlon. The Q4 FY26 PAT was impacted by higher operating and development expenses as the company scales its platform. Raw material price volatility and global supply chain disturbances also posed challenges, but the company is working to pass on these increased costs to customers to maintain margins.

Capital Allocation and Funding Strategy

Anlon plans a new Capex of approximately INR 130 crore for facility expansion. This investment will be funded primarily through a bank term loan of INR 65-70 crore, with the remaining amount sourced from internal funds. The company explicitly stated that it does not plan any equity dilution for this Capex. Management also indicated that they expect to be cash flow positive by the end of FY27, supported by internal accruals and debt, without needing external equity for growth.

Working Capital Management and Receivables

The company acknowledged a steep jump in inventories and other financial assets, attributed to recent acquisitions and increased raw material prices. Management expects the inventory from acquisitions to be sold in Q1 FY27, leading to a 20-25% reduction by FY27 end. Receivable days remain high, currently exceeding 200 days, which is above the market norm of 120-150 days. The company aims to reduce this to at least 180 days by the end of FY27 through stricter payment terms and by stopping supply to non-paying customers.

Product Pipeline and CDMO Opportunities

Anlon is actively developing three molecules for two global innovators, reinforcing its custom manufacturing strategy. The company plans to launch seven new APIs and file 3-5 additional DMFs in FY27 to enhance regulated market penetration. Commercialization of one CDMO product is expected by Q3 FY27, with others following by Q4 FY27 or Q1 FY28. The company also aims for exports to contribute 60% of revenue in FY27.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls